drugset
drugset / Trial / NCT05263817

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

NCT05263817 ↗

Phase 0 Unknown 75 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Timeline

Start
2021-10-08
Primary completion
2024-10-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19/BCMA CAR T-cells Cell therapy — Intravenous

Indications

POEMS syndrome amyloidosis autoimmune hemolytic anemia vasculitis